» Articles » PMID: 10374872

Expression of Inducible Nitric Oxide Synthase (NOS) in Bone Marrow Cells of Myelodysplastic Syndromes

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 1999 Jun 22
PMID 10374872
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Nitric oxide (NO) is a biological mediator which is synthesized from L-arginine by a family of nitric oxide synthases (NOS). We have studied the expression of the inducible NOS (iNOS) by bone marrow cells from the patients with myelodysplastic syndromes (MDS) at the mRNA level by RT-PCR assay and at the protein level by immunohistochemical staining using a specific anti-iNOS monoclonal antibody. The iNOS message was present in 92% of bone marrow tissues from MDS patients (11 out of 12) by an examination using RT-PCR. Basically, iNOS message was negative or very weak in control (1/9) and AML (0/7) cases. This was supported by immunohistochemical findings that the iNOS was positive in most of the bone marrow samples from MDS patients (9 out of 12), while bone marrow cells of control (O out of 12) and AML (O out of 5) cases were basically negative. Double immunostaining for CD68 antigen, which is a marker for macrophage lineage cells, and iNOS was performed on MDS bone marrow sections. iNOS was dominantly localized to bone marrow macrophages, although a part of myeloid cells were also positively stained with anti-iNOS antibody in a part of cases. These results indicated that there is some in vivo induction of iNOS expression for local NO production that might be involved in the dysregulation of hematopoiesis in bone marrow of MDS.

Citing Articles

Bone marrow niches in myeloid neoplasms.

Kitagawa M, Kurata M, Onishi I, Yamamoto K Pathol Int. 2019; 70(2):63-71.

PMID: 31709722 PMC: 7232432. DOI: 10.1111/pin.12870.


Immune Mechanisms in Myelodysplastic Syndrome.

Glenthoj A, Orskov A, Hansen J, Hadrup S, OConnell C, Gronbaek K Int J Mol Sci. 2016; 17(6).

PMID: 27314337 PMC: 4926477. DOI: 10.3390/ijms17060944.


Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome.

Stikarova J, Suttnar J, Pimkova K, Chrastinova-Masova L, cermak J, Dyr J J Hematol Oncol. 2013; 6:58.

PMID: 23958336 PMC: 3765587. DOI: 10.1186/1756-8722-6-58.


Immunologic aspects of hypoplastic myelodysplastic syndrome.

Calado R Semin Oncol. 2011; 38(5):667-72.

PMID: 21943673 PMC: 3187571. DOI: 10.1053/j.seminoncol.2011.04.006.


Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Sloand E, Barrett A Hematol Oncol Clin North Am. 2010; 24(2):331-41.

PMID: 20359629 PMC: 3793398. DOI: 10.1016/j.hoc.2010.02.009.